Company Number: 12765875

Analysis Date: 2025-07-29 18:59 UTC

Financial Health Assessment for HAWXON LTD (as of 31 July 2024)

---

1. Financial Health Score: D

Explanation:
HAWXON LTD shows signs of financial distress in its latest financial year. The company has transitioned from a healthy net asset position in 2023 (£7,517 positive) to a net liability position in 2024 (net assets of -£6,654). This negative equity indicates the company’s liabilities now exceed its assets, a critical symptom of financial weakness. Working capital is also negative, suggesting liquidity strain. These factors collectively warrant a below-average grade, reflecting the need for immediate financial attention.

---

2. Key Vital Signs

Metric	2024 (£)	2023 (£)	Interpretation
Cash at bank	7,055	21,691	Sharp decrease in cash reserves — weaker liquidity.
Current Liabilities	17,321	18,388	Slight reduction, but still high relative to cash.
Net Current Assets (Working Capital)	-10,266	3,303	Negative working capital signals potential cash flow issues.
Net Assets (Equity)	-6,654	7,517	Shift from positive to negative equity — financial distress.
Share Capital	100	100	Minimal share capital, typical for small private companies.
Tangible Fixed Assets (Net)	3,612	4,214	Slight reduction, stable fixed asset base.
Average Number of Employees	1	1	Small scale operation, low fixed costs but limited capacity.

---

3. Diagnosis

• Symptoms of Distress:
  The company’s financial “vitals” reveal a worrying decline in its balance sheet health. The drastic drop in cash reserves alongside negative net current assets indicates the company may be struggling to meet short-term obligations—a classic symptom of liquidity stress. The swing from positive net assets to net liabilities means accumulated losses have eroded shareholder equity, potentially from operating losses or write-downs.

• Underlying Causes:
  The financial statements suggest the company’s business operations may not be generating enough profit or cash flow to sustain growth or cover liabilities. The company operates in combined facilities support activities and financial management/bookkeeping, which are competitive sectors requiring efficient cost controls and strong client billing cycles.

• Risk Indicators:
  Negative equity and working capital deficits raise concerns over the company’s going-concern status if these trends continue. Although no overdue filings or formal insolvency procedures are indicated, these financial symptoms should prompt management and stakeholders to act swiftly.

---

4. Recommendations

• Improve Cash Flow Management:
  Conduct a detailed cash flow forecast to identify timing mismatches in receivables and payables. Accelerate collections and negotiate extended payment terms with suppliers where possible to improve liquidity.

• Cost Control and Expense Review:
  Analyze fixed and variable costs to identify non-essential expenses that can be reduced without impacting core operations. Given the small team size, ensure labour efficiency and consider outsourcing non-core activities if cost-effective.

• Capital Injection or Financing:
  Explore options for fresh equity or short-term financing to bolster working capital. This could stabilize the balance sheet and provide a buffer to support operational improvements.

• Strategic Business Review:
  Reassess the company’s service offerings, pricing strategy, and client base to enhance profitability. Diversification or targeting higher-margin contracts may improve revenue quality.

• Regular Financial Monitoring:
  Implement monthly management accounts and key performance indicators (KPIs) to detect financial “symptoms” early and respond timely.

---

Medical Analogy Summary

HAWXON LTD’s financial health resembles a patient with declining vital signs: a weakening pulse of cash flow and a drop in equity “blood pressure.” The symptoms of distress, such as negative working capital and eroded net assets, warn of a potential “financial collapse” if left untreated. Immediate interventions—akin to stabilizing a patient with IV fluids and medication—are needed to restore liquidity and operational viability.

---